Summary
The main goals of the Supplement Award are to (1) correlate immunoserological responses to early immune
reactions in local tissue environment of the vaccine injection site in healthy donors, and (2) the compare between
healthy controls and patients with hematological disorders or autoimmune disease. We will use a high plex
immuno-fluorescence CODEX imaging panel to profile these skin biopsy samples in the next year of the award.
Using this panel, we can confirm the expression of the SARS-CoV-2 Spike antigen. Interestingly, the SARS-CoV-
2 Spike antigen was detected in the epidermis and dermis of both arms from two donors. Specifically, SARS-
CoV-2 Spike co-expressed with CD303 and CD63 of the unvaccinated arm tissue of a healthy donor and in
cluster 0 of the vaccinated arm of a BCD donor, indicating expression in dendritic cells and basophils. In the next
year to be supported by the Supplement Award, we will be imaging at least 13 more skin tissue sections and
plan to conduct deeper informatics analysis. Additionally, we are performing DBiT-based spatial CITE-seq on
adjacent slides from these 13 skin tissue sections and integrating the data with previously obtained sc-mRNA-
seq data. Furthermore, we have completed immunoserology assays with the serum samples of these donors
and patients. Therefore, once we complete the peripheral tissue spatial imaging and spatial omics sequencing,
the results will be compared to systemic immunological and serological responses over times to help understand
the role of early immune reaction in the development of an effective vaccine protection, in particular, in patients
with blood cancer or autoimmune disease.
Public Health Relevance Statement
Project Narrative
This supplement project aims to develop and apply immuno-serological assays and single-cell spatial
omics assays to investigate the COVID 19 vaccine response in patients with hematologic malignancies
and autoimmunity. The findings will improve our understanding of innate and adaptive immune
mechanisms in COVID-19 vaccination and provide insights for how to prevent or intervene in
future infectious disease pandemic or epidemic, in particular, for protecting patients with compromised
immunity.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AntigensAutoimmune DiseasesAutoimmunityAwardBasophilsBiological AssayBiopsy SpecimenCOVID-19 monitoringCOVID-19 vaccinationCOVID-19 vaccineCellsCellular Indexing of Transcriptomes and Epitopes by SequencingCommunicable DiseasesDataDendritic CellsDermisDevelopmentEnvironmentEpidemicEpidermisFutureGoalsHematologic NeoplasmsHematological DiseaseHematopoietic NeoplasmsImageImmuneImmunityImmunofluorescence ImmunologicImmunologicsInformaticsInjectionsPatientsPeripheralRoleSARS-CoV-2 spike proteinSamplingSerologySerumSiteSkin TissueSlideTissuesVaccinatedVaccinesarmdata integrationimmunoreactionimprovedinsightmRNA sequencingpandemic diseasepreventresponseskin biopsyunvaccinatedvaccine response
National Institute of Allergy and Infectious Diseases
$107,220
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3U01CA260507-02S3
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3U01CA260507-02S3
Patents
No Patents information available for 3U01CA260507-02S3
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3U01CA260507-02S3
Clinical Studies
No Clinical Studies information available for 3U01CA260507-02S3
News and More
Related News Releases
No news release information available for 3U01CA260507-02S3
History
No Historical information available for 3U01CA260507-02S3
Similar Projects
No Similar Projects information available for 3U01CA260507-02S3